GULHANE MEDICAL JOURNAL 2018 , Vol 60 , Issue 4
Retrospective analysis of long-term survival after combination treatment with gemcitabine, oxaliplatin and paclitaxel in patients with refractory or relapsed testicular cancers
İsmail Ertürk1,Birol Yıldız1,Nuri Karadurmuş1,Betül Tosun2,Ramazan Esen3,Ramazan Acar1,Murat Urkan4,Gökhan Erdem5
1University of Health Sciences, Gülhane Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
2Hasan Kalyoncu University, Faculty of Health Sciences, Department of Nursing, Gaziantep, Turkey
3University of Health Sciences, Diskapi Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
4University of Health Sciences, Gulhane School of Medicine, Department of Surgery, Ankara, Turkey
5Private Liv Hospital, Bone Marrow Transplantation Unit, Medical Oncology Clinic, Ankara, Turkey
DOI : 10.26657/gulhane.00040 Aims: Testicular tumors are one of the most common malignancies in males, between 15 and 35 years of age. Testicular cancer patients are treated with the combination of gemcitabine, oxaliplatin and paclitaxel (GOP) in relapsed and refractory disease, but the literature about the GOP treatment is limited. We aimed to demonstrate the real-life data of progressive testicular cancer patients who received GOP treatment.

Methods: Medical records of 17 patients who received GOP treatment at the Gulhane Training and Research Hospital were reviewed retrospectively. Overall response rate (ORR), overall survival (OS) rate and progression-free survival (PFS) of the patients were evaluated.

Results: Overall response was obtained in 58.8% (n=10), and a complete response was achieved in 11.2% (n=2) of the cases. OS time was 14.2 months and the OS rate in the first year was 73.1%. The PFS time was 7.6 months. In most of the patients, thrombocytopenia, anemia and leukopenia were observed during GOP treatment.

Conclusions: GOP is a safe and effective treatment option for relapsed refractory testicular cancer patients with an acceptable ORR, OS and PFS time. Additionally, GOP treatment was associated with cognitive side effects in patients. Keywords : Gemcitabine, paclitaxel, oxaliplatin, testicular cancer